Drug Screening Market worth $11.6 billion by 2026
The global drug screening market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period. The rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches are the major factors driving the growth of this market.
Analytical instruments are expected to dominate the drug screening products market in 2020.
Based on the product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. In 2020, the analytical segment is expected to dominate the market with a share of 53.0%. The high growth in this segment is owing to their recurring requirement and repetitive usage.
Based on the sample type, the urine sample segment is accounted for the largest share of the drug screening market.
By sample type, drug screening market is segmented into urine, breath, oral fluid, hair, and other samples. Among these, the urine sample segment is expected to account for the largest share of 61.5% in 2020. The high growth of this segment is attributed due to the benefits it offers such as easy collection method, high accuracy in the detection of multiple drugs, cost-effectiveness, and instant results.
North America to dominate the drug screening market in 2020.
In 2020, North America is expected to dominate the market with a share of 48.2%, followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug abuse, laws supporting drug screening, the growing burden of accidents due to alcohol impairment, and the presence of key players in the region are driving the growth of the drug screening market in this region.
The drug screening market is highly competitive with the presence of several small and big players. Some of the players offering products for drug screening market include Abbott Laboratories (US), Thermo Fisher Scientific (US), Quest Diagnostics (US), Alfa Scientific Designs (US), Roche (Switzerland), OraSure Technologies (US), MPD Inc. (US), and Shimadzu (Japan).